Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL14853938 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056533 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL10815678 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056827 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9060684 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL375985 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Arauridine SCHEMBL359587 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL7752140 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1804774 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0788506-A2 | L-RIBOFURANOSYL NUCLEOSIDES | GENENCOR INTERNATIONAL, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| US-5559101-A | ANTITUMOR, ANTICARCINOGENIC, HIV | GENENCOR INTERNATIONAL, INC. (US) | 1996-09-24 | — | — | US | claimed |
| US-10882903-B2 | Methods and compositions for treating an alphavirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-01-05 | — | — | US | disclosed |
| US-10869873-B2 | Methods and compositions for treating viral diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| EP-2787999-B1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL DISEASES | UNIV LELAND STANFORD JUNIOR (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180134778-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ALPHAVIRUS INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180000926-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | AGRAWAL, BABITA (CA) | 2018-01-04 | — | — | US | disclosed |
| US-20170000802-A1 | Methods and Compositions for Treating Viral Diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| CN-103145715-B | Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors | F·霍夫曼-罗须公司 | 2016-08-03 | — | — | CN | disclosed |
| US-9364484-B2 | Methods and compositions for treating viral diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| EP-3025727-A1 | METHODS OF TREATING LIVER DISEASE | The J. David Gladstone Institutes (US) | 2016-06-01 | — | — | EP | disclosed |
| CN-1889970-A | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | INTERMUNE INC (US) | 2007-01-03 | — | — | CN | disclosed |
| US-20060269517-A1 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | INTERMUNE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2003039523-A2 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES | EXIQON A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
| EP-0788506-A2 | L-RIBOFURANOSYL NUCLEOSIDES | GENENCOR INTERNATIONAL, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5559101-A | ANTITUMOR, ANTICARCINOGENIC, HIV | GENENCOR INTERNATIONAL, INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | SLC28A1 2154/4885SLC28A2 2642/4885SLC29A1 2625/4885 |
| US-20060269517-A1 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | GBA3, GAA, GANAB | SLC28A1 697/4885SLC28A2 964/4885SLC29A1 1794/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | SLC28A1 2104/4885SLC28A2 2897/4885SLC29A1 1180/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | SLC28A1 1018/4885SLC28A2 1518/4885SLC29A1 629/4885 |
| US-20180000926-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | HAVCR2, CD74, IFNG | SLC28A1 2560/4885SLC28A2 2476/4885SLC29A1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.